Literature DB >> 35167936

NEDD4 degrades TUSC2 to promote glioblastoma progression.

Tadas K Rimkus1, Austin B Arrigo1, Dongqin Zhu1, Richard L Carpenter1, Sherona Sirkisoon1, Daniel Doheny1, Angelina T Regua1, Grace L Wong1, Sara Manore1, Calvin Wagner1, Hui-Kuan Lin2, Guangxu Jin2, Jimmy Ruiz3, Michael Chan4, Waldemar Debinski5, Hui-Wen Lo6.   

Abstract

Whether tumor suppressor candidate 2 (TUSC2) plays an important role in glioblastoma (GBM) progression is largely unknown. Whether TUSC2 undergoes polyubiquitination is unknown. Herein, we report that TUSC2 protein expression is reduced/lost in GBM compared to normal brain due to protein destabilization; TUSC2 mRNA is equally expressed in both tissues. NEDD4 E3 ubiquitin ligase polyubiquitinates TUSC2 at residue K71, and the TUSC2-K71R mutant is resistant to NEDD4-mediated proteasomal degradation. Analysis of GBM specimens showed NEDD4 protein is highly expressed in GBM and the level is inversely correlated with TUSC2 protein levels. Furthermore, TUSC2 restoration induces apoptosis and inhibits patient-derived glioma stem cells (PD-GSCs) in vitro and in vivo. Conversely, TUSC2-knockout promotes PD-GSCs in vitro and in vivo. RNA-Seq analysis and subsequent validations showed GBM cells with TUSC2-knockout expressed increased Bcl-xL and were more resistant to apoptosis induced by a Bcl-xL-specific BH3 mimetic. A TUSC2-knockout gene signature created from the RNA-seq data predicts poor patient survival. Together, these findings establish that NEDD4-mediated polyubiquitination is a novel mechanism for TUSC2 degradation in GBM and that TUSC2 loss promotes GBM progression in part through Bcl-xL upregulation.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioblastoma; Glioma stem cells; NEDD4; TUSC2; Tumor suppressor

Mesh:

Substances:

Year:  2022        PMID: 35167936      PMCID: PMC8920049          DOI: 10.1016/j.canlet.2022.01.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  49 in total

Review 1.  Ubiquitin ligases: cell-cycle control and cancer.

Authors:  Keiichi I Nakayama; Keiko Nakayama
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

Review 2.  Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers.

Authors:  Tadas Rimkus; Sherona Sirkisoon; Alexandra Harrison; Hui-Wen Lo
Journal:  Discov Med       Date:  2017-05       Impact factor: 2.970

3.  FUS1 acts as a tumor-suppressor gene by upregulating miR-197 in human glioblastoma.

Authors:  Jun Xin; Xue-Kui Zhang; De-You Xin; Xian-Feng Li; De-Ke Sun; Yue-Ye Ma; Li-Qiang Tian
Journal:  Oncol Rep       Date:  2015-06-16       Impact factor: 3.906

4.  Fus1/Tusc2 is a novel regulator of mitochondrial calcium handling, Ca2+-coupled mitochondrial processes, and Ca2+-dependent NFAT and NF-κB pathways in CD4+ T cells.

Authors:  Roman Uzhachenko; Sergey V Ivanov; Wendell G Yarbrough; Anil Shanker; Ruslan Medzhitov; Alla V Ivanova
Journal:  Antioxid Redox Signal       Date:  2014-02-04       Impact factor: 8.401

Review 5.  Ubiquitin-mediated control of oncogene and tumor suppressor gene products.

Authors:  Kyoko Kitagawa; Yojiro Kotake; Masatoshi Kitagawa
Journal:  Cancer Sci       Date:  2009-05-19       Impact factor: 6.716

6.  Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer.

Authors:  Ludmila Prudkin; Carmen Behrens; Diane D Liu; Xian Zhou; Natalie C Ozburn; B Nebiyou Bekele; John D Minna; Cesar Moran; Jack A Roth; Lin Ji; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

7.  TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin.

Authors:  Cao Xiaobo; Mourad Majidi; Meng Feng; Ruping Shao; Jing Wang; Yang Zhao; Veerabhadran Baladandayuthapani; Juhee Song; Bingliang Fang; Lin Ji; Reza Mehran; Jack A Roth
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

8.  Regulation of glioma migration and invasion via modification of Rap2a activity by the ubiquitin ligase Nedd4-1.

Authors:  Lei Wang; Bingxin Zhu; Shiquan Wang; Yuxuan Wu; Wenjian Zhan; Shao Xie; Hengliang Shi; Rutong Yu
Journal:  Oncol Rep       Date:  2017-04-11       Impact factor: 3.906

9.  The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.

Authors:  Xi Huang; Huiyao Gu; Enfan Zhang; Qingxiao Chen; Wen Cao; Haimeng Yan; Jing Chen; Li Yang; Ning Lv; Jingsong He; Qing Yi; Zhen Cai
Journal:  Int J Cancer       Date:  2019-08-24       Impact factor: 7.396

10.  Identification of guanine nucleotide-binding protein γ-7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling.

Authors:  Semra Demokan; Alice Y Chuang; Xiaofei Chang; Tanbir Khan; Ian M Smith; Kavita M Pattani; Santanu Dasgupta; Shahnaz Begum; Zubair Khan; Nanette J Liegeois; William H Westra; David Sidransky; Wayne Koch; Joseph A Califano
Journal:  Int J Oncol       Date:  2013-02-06       Impact factor: 5.650

View more
  1 in total

1.  Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.

Authors:  Shichuan Tan; Ryan Spear; Juan Zhao; Xiulian Sun; Pin Wang
Journal:  Front Genet       Date:  2022-06-27       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.